Wells Fargo keeps Amgen at equal weight; raises price target to $435
Wells Fargo maintained an equal-weight rating on Amgen and raised its price target to $435.00 per share from $400.00, according to Benzinga.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.